Evidence map›Paper›PMID 24786974›Full record

ArticleScientific reports2014

Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA.

John P Frampton, Joshua B White, Arlyne B Simon, Michael Tsuei, Sophie Paczesny, Shuichi Takayama

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. ELISA in the multiplex era: potentials and pitfalls.Proteomics. Clinical applications · 2015
    Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John P FramptonDepartment of Biomedical Engineering, University of Michigan.
Joshua B WhiteDepartment of Biomedical Engineering, University of Michigan.
Arlyne B SimonDepartment of Macromolecular Science and Engineering, University of Michigan.
Michael TsueiDepartment of Biomedical Engineering, University of Michigan.
Sophie PaczesnyDepartment of Pediatrics, Indiana University School of Medicine.
Shuichi Takayama1] Department of Biomedical Engineering, University of Michigan [2] Department of Macromolecular Science and Engineering, University of Michigan.
University of Michigan–Ann Arbor · USIndiana University · US

Funding

Graft versus Host Disease Biomarkers: Prediction of Onset and Response to TherapyRC1HL101102 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PACZESNY, SOPHIE · 2009 to 2010
$1000k
NHLBI NIH HHS RC1 HL101102NHLBI NIH HHS RC1HL101102
6 · The paper itself

Abstract

Accurate disease diagnosis, patient stratification and biomarker validation require the analysis of multiple biomarkers. This paper describes cross-reactivity-free multiplexing of enzyme-linked immunosorbent assays (ELISAs) using aqueous two-phase systems (ATPSs) to confine detection antibodies at specific locations in fully aqueous environments. Antibody cross-reactions are eliminated because the detection antibody solutions are co-localized only to corresponding surface-immobilized capture antibody spots. This multiplexing technique is validated using plasma samples from allogeneic bone marrow recipients. Patients with acute graft versus host disease (GVHD), a common and serious condition associated with allogeneic bone marrow transplantation, display higher mean concentrations for four multiplexed biomarkers (HGF, elafin, ST2 and TNFR1) relative to healthy donors and transplant patients without GVHD. The antibody co-localization capability of this technology is particularly useful when using inherently cross-reactive reagents such as polyclonal antibodies, although monoclonal antibody cross-reactivity can also be reduced. Because ATPS-ELISA adapts readily available antibody reagents, plate materials and detection instruments, it should be easily transferable into other research and clinical settings.

Indexed as

AntibodiesBiomarkersBone Marrow TransplantationCross ReactionsEnzyme-Linked Immunosorbent AssayGraft vs Host DiseaseHumansAntibodiesBiomarkers

Identifiers

PMID24786974
PMCPMC4007081
OpenAlexW2064361552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.